VELCADE, also known by its generic name bortezomib, is a prescription medication used in the treatment of certain types of cancer, most notably multiple myeloma and mantle cell lymphoma. It belongs to a class of drugs known as proteasome inhibitors, which work by blocking the action of proteasomes within cells. Proteasomes play a crucial role in regulating cell function and growth by breaking down proteins that are damaged or no longer needed. By inhibiting these proteasomes, VELCADE disrupts the normal functioning of cancer cells, leading to their death. This medication is typically administered through injection, either intravenously or subcutaneously, depending on the specific treatment regimen. VELCADE has been a significant advancement in the treatment of these cancers, offering hope to patients with these challenging conditions.